BEST UNLIMITED TURBO LONG CERTIFICATE - IPSEN | Market Closed - Euronext Paris 17:30:01 30/04/2024 BST | ||
| 1.905 EUR | +5.54% |
|
| Current month | +8.55% | ||
| 1 month | +8.55% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
IPSEN
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/04/24 | 1.905 | +5.54% | 49 |
| 29/04/24 | 1.805 | -3.22% | 43 |
| 26/04/24 | 1.865 | +2.75% | 35 |
| 25/04/24 | 1.815 | -1.63% | 57 |
| 24/04/24 | 1.845 | +2.22% | 46 |
Real-time Euronext Paris
Last update April 30, 2024 at 05:30 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | IPSEN |
| Issuer | 
Société Générale
|
| 34S8S | |
| ISIN | DE000SD3MHF7 |
| Date issued | 05/02/2021 |
| Strike | 76.46 € |
| Maturity | Unlimited |
| Parity | 20 : 1 |
| Emission price | 0.51 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.965 € |
|---|---|
| Lowest since issue | 0.08 € |
Company Profile
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows:
- oncology (75.2%);
- neuroscience (21.1%);
- rare diseases (3.7%).
At the end of 2023, the group had 4 research and development centres located in France, the United Kingdom, the United States and China, and 4 manufacturing sites worldwide.
Net sales are distributed geographically as follows: Europe (40.2%), North America (33.3%) and other (26.5%).
Sector
-
Consensus: Ipsen
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
114.1
EUR
Average target price
125.2
EUR
Spread / Average Target
+9.75%
- Stock Market
- Certificates
- 34S8S Certificat
